Raltegravir: an integrase inhibitor for HIV-1.
Article Details
- CitationCopy to clipboard
Evering TH, Markowitz M
Raltegravir: an integrase inhibitor for HIV-1.
Expert Opin Investig Drugs. 2008 Mar;17(3):413-22. doi: 10.1517/13543784.17.3.413 .
- PubMed ID
- 18321239 [ View in PubMed]
- Abstract
BACKGROUND: The need to develop antiretroviral agents with novel mechanisms of action persists for the treatment of both antiretroviral- experienced and antiretroviral-naive patients with HIV/AIDS. This is mandated, in part, by the perpetual advent of antiretroviral-resistant HIV-1 strains. Raltegravir has been shown to specifically inhibit the essential, HIV-1-encoded, integrase enzyme. As a result, this agent represents a promising chemotherapeutic agent for the treatment of HIV/AIDS. OBJECTIVE: To form an evidence-based determination of the clinical efficacy, pharmacokinetics and safety profile of raltegravir. METHOD: We discuss available peer-reviewed publications, preliminary data presented in abstract from relevant scientific meetings and data available from the US Food and Drug Administration (FDA). RESULTS/CONCLUSION: Current evidence strongly supports raltegravir use in highly active antiretroviral therapy (HAART) regimens constructed to treat patients failing current therapies with multi-drug-resistant HIV-1. Additional data are needed to determine its role in the treatment of less advanced patients. Issue surrounding long-term adverse effects and genetic barriers to raltegravir resistance will be critical in determining the potential of this agent.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Raltegravir Integrase Protein Human immunodeficiency virus 1 YesInhibitorDetails